Generic Drug News and Research

RSS

Generic Drugs are official nonbrand names by which medicines are known. Generic names usually refer to the chemical name of the drug.

Health solutions developed in lower-income countries will help bring end to aid

"It is not just quantity of aid that counts nowadays, but the quality and perspective of that aid, as well as innovation, investment and experience domestically," Jonathan Glennie, a research fellow at the Overseas Development Institute, writes in the Guardian's "Poverty Matters Blog."

27 Mar 2012

1 in 5 Australians have taken an expired medicine

NPS is urging all Australians to clean out their medicine cabinets today as part of national Be Medicinewise Week 2012. New research from NPS found around 1 in 5 people reported ever having taken an expired medicine.

26 Mar 2012

FDA approves Teva's QNASL nasal aerosol corticosteroid

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has approved QNASL Nasal Aerosol, a new, "dry" nasal aerosol corticosteroid that treats seasonal nasal and year-round nasal allergy symptoms in adults and adolescents 12 years of age and older.

26 Mar 2012

IGI fourth quarter total revenues increase 21% to $2.1M

IGI Laboratories, Inc., a New Jersey based topical generic drug development and manufacturing company, provided its financial results for the fourth quarter and year ended December 31, 2011.

21 Mar 2012

Indian patent court licenses generic copy of Bayer’s blockbuster anticancer drug

Last week an Indian patent court shocked the $600 billion global pharmaceutical business by ordering Bayer, the German health care giant, to allow a tiny Indian generic drug company to sell cheap copies of the blockbuster cancer drug Nexavar – even though everyone agrees that the drug is protected by a patent. Instead, the court decided that Bayer had an obligation to make Nexavar available to people in India who needed it.

20 Mar 2012

NEJM publishes results from Teva's laquinimod Phase III study on RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced the publication of results from the laquinimod Phase III ALLEGRO study in the March 15 issue of The New England Journal of Medicine.

16 Mar 2012

Teva gets exclusive 180 days to market generic antidepressant and anti-anxiety pill Lexapro

Teva Pharmaceutical Industries Ltd. Has won U.S. approval to sell the first generic version of Lexapro for depression and anxiety. Teva has been granted a 180-day exclusivity, so no other firm can market the generic medication in the United States in that timeframe, the Food and Drug Administration (FDA) said in a news release.

15 Mar 2012

First-ever compulsory license issuance in India could have implications for HIV medication

"On Monday, the Indian Patent Office effectively ended German drug maker Bayer's monopoly for its cancer drug Nexavar and issued its first-ever compulsory license allowing local generic maker Natco Pharma to make and sell the drug cheaply in India," Reuters reports.

15 Mar 2012

Teva commences commercial launch of Escitalopram Oxalate Tablets

Teva Pharmaceutical Industries Ltd. announced today that it has commenced commercial launch of Escitalopram Oxalate Tablets, the Company's generic version of Forest Laboratories' depression and generalized anxiety disorder treatment, Lexapro Tablets.

15 Mar 2012

FDA approves Teva's ProAir HFA with dose counter for asthma, COPD and EIB

Teva Respiratory announced today that the U.S. Food and Drug Administration (FDA) has approved ProAir HFA with a dose counter for use in patients 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.

8 Mar 2012

Get ready for Be Medicinewise Week 2012

Building on the success of last year’s inaugural event, the week will urge all Australians to stop, think and learn more about the medicines they are using and encourage them to seek information to make better decisions about their health.

8 Mar 2012

FDA takes more time to decide on the fate of BMS & Pfizer’s joint venture anticlotting drug Eliquis

The U.S FDA have pushed back the deadline for deciding whether to approve an experimental anticlotting drug developed jointly by Pfizer Inc. and Bristol-Myers Squibb Co. The companies said late Wednesday that the Food and Drug Administration has set a new target date of June 28 for deciding whether to approve Eliquis. That’s three months later than originally scheduled.

2 Mar 2012

Glenmark Generics recalls batch of birth control pills

Drug manufacturer Glenmark Generics, announced last Friday, that it is recalling seven lots of birth control pills because in some packages, the pills were in the wrong order.

27 Feb 2012

Making a medicinewise choice between brands

Following reports the first generic version of atorvastatin will be hitting pharmacy shelves this week, NPS is urging consumers to be medicinewise when making a choice between medicine brands.

22 Feb 2012

Insulin production may persist for decades after onset of type 1 diabetes

Massachusetts General Hospital (MGH) research has found that insulin production may persist for decades after the onset of type 1 diabetes. Beta cell functioning also appears to be preserved in some patients years after apparent loss of pancreatic function. The study results appear in the March issue of Diabetes Care.

22 Feb 2012

ACAAI, Teva Respiratory partner to bring free asthma screenings nationwide

The American College of Allergy, Asthma and Immunology (ACAAI) recognizes Teva Respiratory for its continued leadership and support of important educational issues related to respiratory health, particularly under diagnosed and poorly managed asthma and exercise-induced bronchoconstriction. ACAAI announced today that they will partner again this year with Teva Respiratory to bring free asthma screenings to communities nationwide.

16 Feb 2012

Teva fourth quarter net revenues increase 28% to $5.7 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter and year ended December 31, 2011.

15 Feb 2012

FDA requests a budget of $4.5 billion to protect and promote public health

The U.S. Food and Drug Administration is requesting a budget of $4.5 billion to protect and promote the public health as part of the President's fiscal year (FY) 2013 budget – a 17 percent increase over the FDA enacted budget for FY 2012.

14 Feb 2012

Proposed intellectual property agreement between E.U., India could affect generic drug exports, advocacy groups say

The Independent examines how "the cheap supply of antiretroviral drugs to people with AIDS across the world could be choked by an 'intellectual property' deal ... being negotiated on Friday at the 12th E.U.-India summit in New Delhi between the President of the European Commission, José Manuel Barroso, and the Indian Prime Minister Dr. Manmohan Singh."

13 Feb 2012

FDA lays guidelines for “biosimilar” biotech drugs

The proposed rules, issued on Thursday, require studies showing that the generic copies are “highly similar” to the originals, but there are several ways that might be proven. Because of their complexity, generic copies of biotech drugs - first introduced in the 1980s - are known as “biosimilars.” The worldwide market for copies of biotech medicines will grow to $3.7 billion by 2015, from just $243 million in 2010, as more than 30 branded biologics with sales of $51 billion lose patent exclusivity, according to market analysis firm Datamonitor.

12 Feb 2012